Objective: HIV infection and aging are both associated with neurodegeneration. However, whether the aging process alone or other factors associated with advanced age account for the progression of neurodegeneration in the aging HIV-positive (HIV1) population remains unclear.
severity of HIV infection and medical comorbidities which may influence the trajectory of HIV infection and cognitive and brain aging.
Neuroimaging-based estimates of the deviance between an individual's chronological age and predicted brain age-termed brain age gap (BAG)-are sensitive to augmented and/or accelerated brain aging (Cole et al., 2017a (Cole et al., , 2017b ). While no current study has investigated BAG in WM microstructure using diffusion tensor imaging (DTI), recently, using brain volume, Cole et al. (2017a) demonstrated that BAG in the volume of brain grey and white matter is greater in HIVinfected individuals than in HIV2 controls. Although no significant relationships between BAG and nadir CD41 or HIV disease duration were reported, the authors investigated white matter volume, rather than white matter microstructure (using DTI) and in a sample of HIV1 participants with undetectable viral loads. Thus, it is unclear to which degree findings of "attenuated brain aging" in HIV (Cole et al., 2017a; Horvath & Levine, 2015; Kuhn et al., 2017) may be mediated by primary or secondary processes related to the infection. It is also unclear what effects these processes may have on WM microstructure. Therefore, this study sought to expand on previous findings by investigating the predicted-BAG in WM microstructure using DTI metrics of white matter patency. This project also sought to further elucidate the effect of HIV severity indices and non-HIV-related medical comorbidities on accentuated WM aging.
Here, we used a machine learning approach to quantify brain aging based on DTI. A support vector machine model trained in a large and independent training-set of healthy controls was used to predict age in HIV1 and comparable HIV2 individuals. We tested for group differences in BAG between HIV1 and HIV2, and for associations with cognitive function and HIV disease factors and medical comorbidities within the HIV1 group.
| M E TH ODS

| Participants
Participants included a testing dataset of 104 (72 HIV1 (confirmed by serologic testing); 32 HIV2) adults (M age 5 50.17; SD 5 12.82) who were enrolled as part of a larger study (K23 MH095661; PI: ADT). All participants who had DTI imaging data available were included in this study. All procedures were in accordance with the Declaration of Helsinki, reviewed and approved by the University of California, Los Angeles (UCLA) Institutional Review Board prior to enrollment and all participants provided written informed consent.
The training set used for the age prediction model comprised 765 healthy community dwelling individuals aged 20-78 years sampled from two different cohorts, including the ongoing STROKEMRI study at the University of Oslo (UiO; n 5 177, M age 5 57.59; SD 5 15.05, 60% female, PI: LW) and the Cambridge Centre for Ageing and Neuroscience (Taylor et al., 2017 ) (Cam-CAN) (n 5 588, M age 5 52.31; SD 5 17.38, 50% female) from the Cambridge Center for Ageing and Neuroscience (Shafto et al., 2014) (CamCAN) . Data used in the preparation of this work were obtained from the CamCAN repository (available at http://www.mrc-cbu.cam.ac.uk/datasets/camcan/) (Shafto et al., 2014; Taylor et al., 2017) . All procedures were in accordance with relevant IRBs.
| Psychiatric assessment
In the test sample, the Structured Clinical Interview (SCID) for DSM-IV (First, Gibbon, Spitzer, & Benjamin, 1997) , and structured questionnaires were used to screen for neurological, psychiatric, and medical confounds including: history of seizure disorder or other neurologic disorder; history of concussion or traumatic brain injury sufficient to warrant medical attention; history of Axis I psychiatric disorder or current substance use disorder (SCID-IV diagnostic criteria); current prescriptions for psychotropic medication, except for anxiolytics and antidepressants; current substance dependence or stimulant use, comorbid infection (e.g., Hepatitis C), HIV-associated CNS opportunistic infection (e.g., CNS toxoplasmosis), or CNS neoplasm. Participants were also screened for contraindications to MRI.
| Cognitive assessments
In the test sample, participants completed a comprehensive neuropsychological test battery used in prior studies , which assessed neurocognitive function at both the global and domain levels.
Six cognitive domains were measured: (1) Processing Speed: Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Symbol and Symbol Search subtests (Wechsler, 2008) , Trail Making Test-Part A (Reitan, 1958) , and Stroop-Color Naming and Word Reading (Golden, 1978) ; (2) Learning: Hopkins Verbal Learning Test-Revised (Brandt & Benedict, 2001) and Brief Visuospatial Memory Test-Revised (Benedict, 1997); (3) Memory: Hopkins Verbal Learning Test-Revised (Brandt & Benedict, 2001) and Brief Visuospatial Memory Test-Revised (Brandt & Benedict, 2001 ,Benedict, 1997 ) (delayed recall); (4) Language/Verbal Fluency: Controlled Oral Word Association Test (Benton, Hamsher, & Sivan, 1983 ) (FAS and Animals); (5) Executive Function:
WAIS-IV Letter-Number Sequencing subtest (Wechsler, 2008) , Trail Making Test-Part B (Reitan, 1958) , and Stroop-Color-Word Interference Test (Golden, 1978) ; and (6) Motor Speed: Grooved Pegboard test (Heaton, Grant, & Matthews, 1992) (dominant and nondominant hands).
We converted raw test scores into within-sample z scores and then averaged them to create neurocognitive domain z scores. We calculated the global neurocognition score by averaging the z scores from all of the neuropsychological test variables. Given that the relationship between age and neurocognitive performance in HIV is a primary aim of this study, within-sample z scores were computed instead of demographically adjusted T scores.
| Immune status assessment
In the testing dataset, HIV1 participants self-reported nadir CD41 and lifetime highest viral load were used to assess past immune status. Participants also underwent venipuncture to test current CD41 and HIV viral load. HIV duration was calculated as the number of years since the participant's self-reported HIV diagnosis. Next, participants were classified as either "pre-HAART" (highly active antiretroviral therapy) or "post-HAART" based on whether their initial HIV diagnosis was before or after 1996 (Bartlett, 2006) . Further, a "medical comorbidity burden" index score was computed from the medical history taken during the routine interview all participants completed during data collection.
Participants were assigned a "1" if they endorsed a history of each of the following medical conditions: cerebrovascular risk factors including hypertension, heart failure, COPD, anemia, diabetes; endocrine dysfunction including thyroid disease, testosterone therapy, estrogen therapy; kidney disease. Participants were assigned a "0" for all medical conditions they did not endorse. The "medical comorbidity burden" score was then computed as a sum of these conditions, resulting in a scale ranging from 0 (no medical comorbidities) to 9 (endorsed all medical comorbidities identified). ) and 3 non-diffusion-weighted volumes were obtained using a twice refocused spin-EPI with 66 3 2.0 mm axial slices (no gap), TR 5 9,100 ms, TE 5 104 ms, voxel size 5 2.0 3 2.0 3 2.0 mm, scan time 573 s. Only the b 5 0 and b 5 1,000 shells were used for DTI analysis in this study. All DWI images were quality controlled and visually inspected prior to being preprocessed and analyzed.
| MRI acquisition and analysis
DWI scans from UCLA, UiO, and Cam-CAN were processed simultaneously through the same pipeline to harmonize imaging methods across sites. All imaging data were processed using FMRIB software Library (Jenkinson, Pechaud, & Smith, 2005 ) (FSL, www.fmrib.ox.ac.uk. fsl). DWI data were motion and eddy current corrected using EDDY (Andersson & Sotiropoulos, 2016) , skull stripped using BET (Jenkinson et al., 2005) , and then diffusion tensors were fit to the data using dtifit WM underling the hippocampus; inferior, middle, and superior cerebellar peduncles; cerebral peduncle; pontine; fornix; stria terminalis; corticospinal tract; medial lemniscus; inferior and superior longitudinal fasciculus; superior fronto-occipital fasciculus; uncinate fasciculus; genu, body, tapetum, and splenium of the corpus callosum.
| Statistical analysis 2.3.1 | Group demographics
Participant characteristics (e.g., age, education, past drug use) between HIV1 and HIV2 groups were compared using one-way analysis of variance (ANOVA). Group differences in dichotomous factors (e.g., sex, ethnicity, urinalysis results) were assessed using chi-square analyses.
We used p < .05 as our cutoff for statistical significance for these demographic analyses.
| Age prediction and brain age gap
UiO and Cam-CAN data were used to train a support vector regression model (SVR) to predict participant age using FA, L1, RD, and MD from atlas-derived ROIs (the exact same regions described above; Gaser et al., 2013; Hua et al., 2008; Wakana et al., 2007) as features. Similar methods have been employed using imaging data previously (Cole et al., 2017a,b; Mwangi, Hasan, & Soares, 2013) including using DTI to assess participant age in a healthy cohort (Wilkinson & Robertson, 2006) . SVR was conducted in Matlab (https://mathworks.com/help/ stats/fitrsvm.html) using the implementation "fitrsvm" with a linear kernel, automatic hyperparameter tuning and Sequential Minimal Optimization. Given that multiple MR scanners were used to collect the HIV and training data, scanner was used as a regressor on the features to control for interscanner variability. The model accuracy was validated using 10-fold cross-validation on the training set. After successful validation, the trained SVR was used to predict age of participants in the independent UCLA sample (HIV1/HIV2). For each individual, BAG was computed by subtracting the participant's predicted brain age by their chronologic age. Univariate analysis of covariance (ANCOVA) then compared BAG between UCLA HIV serostatus groups, controlling for chronological age and sex.
| Associations between brain age gap immune status and cognitive performance
Within HIV1 subjects, a stepwise hierarchical linear regression was conducted to investigate the relationship between BAG and chronological age, nadir CD41, lifetime highest HIV RNA viral load, and medical comorbidity index, and all possible interactive relationships between age and other dependent variables using a stepwise entry model. Correlation analyses were used to investigate the relationship between BAG and cognitive performance in the UCLA HIV1 group.
Correlations were conducted between BAG and individual cognitive domains (e.g., attention, memory) and global cognitive performance. We report both bivariate correlations as partial correlations covarying for premorbid intellectual ability (Wide Range Achievement Test, 4th Edition (WRAT-4; Brew, Crowe, Landay, Cysique, & Guillemin, 2009 ). False discovery rate (FDR) was used to correct for multiple comparisons.
| R E SU LTS
| Demographic group comparison
In the test dataset, the HIV1 and HIV2 seronegative groups did not significantly differ on age, years of education, ethnicity, or sex ( Figure 2 depicts the age prediction results. Figure 3 is the scatterplot depicting the 10-fold cross-validation of the SVR within the training data set.
In the testing dataset, HIV1 individuals showed higher differences between their brain age and their chronological age than HIV2 coun- 
| Neurocognition, immune status, and brain age gap
All results reported below withstood FDR correction. 
| D I SCUSSION
This study used machine learning along with a large training data set of normal WM aging to examine HIV-associated WM microstructural alterations and related this WM degeneration to cognitive impairment.
Using an SVR trained with this healthy aging cohort to reliably predict participant age based on metrics of WM microstructure, we found that the brain WM age difference (BAG) was significantly higher in our HIV1 group than in the highly comparable HIV2 group. Further, BAG widened with increasing age, suggesting that advancing age is a risk factor for neurodegeneration. Additionally, larger BAG was associated with worse cognitive performance, indicating that this neurodegeneration may be related to deleterious changes in cognition. Although chronological age was not significantly correlated with prediction error, confirmatory analyses verified that these significant associations between BAG and cognitive performance remained after controlling for participant true age.
Importantly, in our sample in which 11% of the HIV1 participants To the best of our knowledge, this is the first study to demonstrate an HIV-associated accentuated aging process in WM microstructure, | 2537 using DTI. These findings are generally consistent with the literature, including a recently published study showing an HIV-related accentuated aging process in combined grey matter/white matter volume (Cole et al., 2017a) . Similar to that reported by Cole et al., we did not find significant relationships between WM BAG and Nadir CD4 or HIV duration. Our findings expand upon these previous results by providing data suggesting the mechanism through which this augmented aging process deleteriously affects WM microstructure. Our results also further the literature in that we found a significant relationship between BAG and peak HIV RNA viral load and a significant age 3 peak viral load interactive effect on BAG, indicating that the effects of disease burden on brain integrity are more pronounced with advanced age.
Furthermore, these findings indicate the significant advantages of using BAG to predict HIV-associated white matter aging over other methods. The BAG findings were much stronger than our conventional age-trajectory findings, indicating that the SVR-based brain age approach we used is a sensitive approach to reveal group differences beyond simple differences in mean DTI measures. Additionally, BAG outperformed each individual DTI metric in its ability to discriminate between HIV1
and HIV2 participants and demonstrate the effect of HIV infection on advancing brain white matter age. BAG also may be more useful than, or at the very least a meaningful compliment to, hyper-/hypointense lesion volume and count which has been shown to relate to HIV infection and cognitive performance, but not to HIV clinical variables or HIVassociated aging (Ciesla & Roberts, 2001; McMurtray, Nakamoto, Shikuma, & Valcour, 2008; Su et al., 2016) . Additionally, BAG is a relatively easy metric to understand and thus it circumvents the cumbersome and difficult to interpret multivariate score often used with DTI metrics which are inherently difficult to connect to clinical variables. In contrast, BAG was successfully and clearly connected to both HIV clinical variables (e.g., HIV RNA viral load) and neurocognitive performance.
It is important to consider these findings also in the context of the psychosocial stressors and associated comorbidities associated with living with HIV. For example, the HIV1 sample evidenced greater rates of comorbidities, both medical (which were included in the model herein) and psychiatric (e.g., depression, which was not included in the model). It is unclear in the literature to what extent depression is a secondary reaction to living with HIV or is a neurologic symptom of the predominantly frontal-subcortical clinical profile of the disease. Therefore, it remains unclear whether the augmented aging findings are related directly and solely to the effects of the HIV virus on the brain or if they are also related to secondary effects of these HIV-associated increased comorbidities. This is particularly worthy of follow-up investigation given that depressive disorders are the most prevalent mental health disorders associated with HIV and studies have shown that depression can be associated with neurodegeneration and increased brain age (Cole et al., 2018) .
There are limitations of this study worth noting. First, the crosssectional nature of this study hinders our ability to make inferences about the rates of neuroanatomic changes in HIV. Importantly, this limited our ability to determine whether our findings relate to a more static, vestigial process which adds to or augments the aging process in HIV, or whether in fact these results are related to a dynamic, accelerated aging process. This is an important distinction and clinically meaningful question, particularly as the HIV1 population continues to age in the post-HAART era, and must be addressed using a longitudinal model. A recent longitudinal publication (Cole et al., 2018) demonstrated that HIV1 participants demonstrated greater predicted brain age than HIV2 controls when analyzed at cross-section. However, when followed longitudinally, the HIV1 and HIV2 groups evidenced comparable rates of change in neuroimaging markers, suggesting that, when receiving successful treatment, people living with HIV are not at risk for accelerated brain aging over 2 years. Longer longitudinal studies will help clarify whether or not this pattern remains steady over time.
Next, the SVR-modeling of the DTI data appeared to be less accurate (MAE 5 7.39 years) than that using T1-MRI to measure brain volume (MAE 5 5.01 years) (Cole et al., 2017a) . This could be due to differences in the neuroimaging methodology used (e.g., size, variability, and number of features of training sample set). However, it is also the case that we sought to test a different biological entity (DTI-based WM microstructure), and as such a direct comparison between SVRderived brain ages may not be appropriate, as Cole et al sought to determine a best-predicted brain age based on grey/white matter volume and we sought to determine the best-predicted age of WM microstructure. The fact that data were acquired at multiple sites using different MR scanner could be a factor and a limitation. However, scanner was included as a variable in the model and the data was homogenized using a single, uniform processing pipeline which has become an accepted standard of practice in the field and indeed has been used in similar machine learning papers (Cole et al., 2017a (Cole et al., , 2017b where the training data and the disease-specific data were collected at separate sites using different scanners and non-identical scanning parameters.
Therefore, this is a limitation of note but one whose impact on the findings was minimized to the best of our abilities. Additionally, although the TBSS method applied should limit the impact of atrophy on our findings, this study did not employ any specific control regarding possible WM lesions. Given that WM lesions have been reported in the brains of HIV1 patients, it is possible that our prediction of WM age could be improved had we included WM lesions from any affected patient in the model. Further, there are some inherent demographic differences (e.g., race/ethnicity) in the training datasets (from England and Norway) and the test dataset (from Los Angeles). While we attempted to control for these by comparing our UCLA HIV1 participants to UCLA HIV2 participants who were highly matched on demographic variables and assessing the effect of race/ethnicity on the outcomes, it remains possible that such demographic or even genetic variables could contribute to our findings, though we believe this is less likely for several reasons including the SVR model fit statistics and similar findings from Cole et al. (2017a) . Furthermore, there are some limits to the generalizability of this study. These include the exclusion of participants with substance use disorders and Axis I diagnoses, the (although nonsignificant) fact that our sample included fewer HIV1 women, and the fact that the older HIV1 adults are long term survivors from the pre-HAART era and may not be representative of HIV1 adults reaching older age in the near future who were diagnosed in the post-HAART era. Importantly though, it is possible that comorbid substance abuse and/or psychiatric disorders may increase the risk of premature brain aging. Although the current CD41 and viral load data used in this study were extracted from blood samples collected during the course of this study, nadir CD41 and highest lifetime viral load were self-reported by participants. Additionally, the DTI-based WM metrics were extracted from the entire white matter skeleton, rather than from individual WM tracts (e.g., uncinate fasciculus). This method limits the spatial resolution of our technique. Future examinations between specific tracts with respect to white matter aging are warranted.
Despite these limitations, the findings of this study support the hypothesis of HIV-associated augmented brain aging and provide a unique contribution to the existing literature by demonstrating that the mechanism by which this process occurs in WM microstructure appears to be related to HIV-associated neurodegeneration, including axonal injury, loss of axonal density, and reduced patency of axons that likely occurs via similar cellular mechanisms as typical aging. Importantly, neuroimage-derived age predictors may indeed be biomarkers of normal and pathologic aging processes. Therefore, this technique may be generalizable to other disease processes which may affect the aging process, including neurodegenerative disorders (e.g., Alzheimer's disease) and other neuro-medical illnesses. This technique may also be useful in identifying patients at risk for cognitive decline, functional limitations, and early mortality (Cole et al., 2017b) . ac.uk/datasets/camcan/) (Taylor et al., 2017; Shafto et al., 2014) . 
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